Your browser doesn't support javascript.
A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination.
Colwill, Karen; Galipeau, Yannick; Stuible, Matthew; Gervais, Christian; Arnold, Corey; Rathod, Bhavisha; Abe, Kento T; Wang, Jenny H; Pasculescu, Adrian; Maltseva, Mariam; Rocheleau, Lynda; Pelchat, Martin; Fazel-Zarandi, Mahya; Iskilova, Mariam; Barrios-Rodiles, Miriam; Bennett, Linda; Yau, Kevin; Cholette, François; Mesa, Christine; Li, Angel X; Paterson, Aimee; Hladunewich, Michelle A; Goodwin, Pamela J; Wrana, Jeffrey L; Drews, Steven J; Mubareka, Samira; McGeer, Allison J; Kim, John; Langlois, Marc-André; Gingras, Anne-Claude; Durocher, Yves.
  • Colwill K; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Galipeau Y; Department of Biochemistry, Microbiology, and Immunology University of Ottawa Ottawa ON Canada.
  • Stuible M; Mammalian Cell Expression, Human Health Therapeutics Research Centre National Research Council Canada Montréal QC Canada.
  • Gervais C; Mammalian Cell Expression, Human Health Therapeutics Research Centre National Research Council Canada Montréal QC Canada.
  • Arnold C; Department of Biochemistry, Microbiology, and Immunology University of Ottawa Ottawa ON Canada.
  • Rathod B; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Abe KT; Present address: Treadwell Therapeutics Toronto ON Canada.
  • Wang JH; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Pasculescu A; Department of Molecular Genetics University of Toronto Toronto ON Canada.
  • Maltseva M; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Rocheleau L; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Pelchat M; Department of Biochemistry, Microbiology, and Immunology University of Ottawa Ottawa ON Canada.
  • Fazel-Zarandi M; Department of Biochemistry, Microbiology, and Immunology University of Ottawa Ottawa ON Canada.
  • Iskilova M; Department of Biochemistry, Microbiology, and Immunology University of Ottawa Ottawa ON Canada.
  • Barrios-Rodiles M; The Centre for Infection, Immunity, and Inflammation University of Ottawa Ottawa ON Canada.
  • Bennett L; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Yau K; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Cholette F; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Mesa C; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Li AX; Division of Nephrology Department of Medicine Sunnybrook Health Sciences Centre Toronto ON Canada.
  • Paterson A; National Microbiology Laboratory Public Health Agency of Canada Winnipeg MB Canada.
  • Hladunewich MA; Department of Medical Microbiology and Infectious Diseases University of Manitoba Winnipeg MB Canada.
  • Goodwin PJ; National Microbiology Laboratory Public Health Agency of Canada Winnipeg MB Canada.
  • Wrana JL; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Drews SJ; Department of Microbiology, at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Mubareka S; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • McGeer AJ; Department of Microbiology, at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Kim J; Division of Nephrology Department of Medicine Sunnybrook Health Sciences Centre Toronto ON Canada.
  • Langlois MA; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
  • Gingras AC; Department of Medicine University of Toronto Toronto ON Canada.
  • Durocher Y; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health Toronto ON Canada.
Clin Transl Immunology ; 11(3): e1380, 2022.
Article in English | MEDLINE | ID: covidwho-1750347
ABSTRACT

Objectives:

Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been instrumental in detecting previous exposures and analyzing vaccine-elicited immune responses. Here, we describe a scalable solution to detect and quantify SARS-CoV-2 antibodies, discriminate between natural infection- and vaccination-induced responses, and assess antibody-mediated inhibition of the spike-angiotensin converting enzyme 2 (ACE2) interaction.

Methods:

We developed methods and reagents to detect SARS-CoV-2 antibodies by enzyme-linked immunosorbent assay (ELISA). The main assays focus on the parallel detection of immunoglobulin (Ig)Gs against the spike trimer, its receptor binding domain (RBD) and nucleocapsid (N). We automated a surrogate neutralisation (sn)ELISA that measures inhibition of ACE2-spike or -RBD interactions by antibodies. The assays were calibrated to a World Health Organization reference standard.

Results:

Our single-point IgG-based ELISAs accurately distinguished non-infected and infected individuals. For seroprevalence assessment (in a non-vaccinated cohort), classifying a sample as positive if antibodies were detected for ≥ 2 of the 3 antigens provided the highest specificity. In vaccinated cohorts, increases in anti-spike and -RBD (but not -N) antibodies are observed. We present detailed protocols for serum/plasma or dried blood spots analysis performed manually and on automated platforms. The snELISA can be performed automatically at single points, increasing its scalability.

Conclusions:

Measuring antibodies to three viral antigens and identify neutralising antibodies capable of disrupting spike-ACE2 interactions in high-throughput enables large-scale analyses of humoral immune responses to SARS-CoV-2 infection and vaccination. The reagents are available to enable scaling up of standardised serological assays, permitting inter-laboratory data comparison and aggregation.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Vaccines Language: English Journal: Clin Transl Immunology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study Topics: Vaccines Language: English Journal: Clin Transl Immunology Year: 2022 Document Type: Article